Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Lineage Cell Therapeutics's total debt was $18.00K at Dec 31, 2017. For fiscal 2017 it was $18.00K, down 85.0% from the year before. The highest annual figure on record is $246.00K in fiscal 2015.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $18.00K | -85.0% |
| FY2016 | Dec 31, 2016 | $120.00K | -51.2% |
| FY2015 | Dec 31, 2015 | $246.00K | +693.5% |
| FY2014 | Dec 31, 2014 | $31.00K | – |
| FY2013 | Dec 31, 2013 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2017 | Dec 31, 2017 | $18.00K | -85.0% |
| Q3 FY2017 | Sep 30, 2017 | $44.00K | -74.6% |
| Q2 FY2017 | Jun 30, 2017 | $95.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $95.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $120.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $173.00K | – |
See a number that looks wrong?